ALTSTATION.IO

Amgen Inc. (AMGN) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$375.88

Change

+2.20%

Market Cap

$202.60B

Avg Volume

2.9M

Company Overview

Amgen Inc. discovers, develops, and manufactures therapeutics primarily for serious illnesses. Their product portfolio includes well-known drugs like Enbrel, Prolia, and Repatha, targeting conditions such as rheumatoid arthritis, osteoporosis, and cardiovascular issues. They primarily sell to healthcare providers, including hospitals and clinics, as well as through pharmacies. The company operates globally, focusing on innovative biotechnology solutions to improve patient care.

Amgen is a market leader in the biotechnology sector, holding a strong position with a diverse range of blockbuster drugs. Their competitive edge stems from robust research and development capabilities, allowing them to stay ahead in innovation. However, they face competition from other biotech giants like AbbVie and Gilead, as well as pressure from biosimilars that could erode market share for established products. The ongoing trend toward value-based care also poses a challenge, as payers demand more evidence of cost-effectiveness.

As of now, Amgen is in a growth phase, driven by the successful launches of new treatments and ongoing investments in R&D. Recent highlights include a significant expansion in their oncology portfolio through collaborations, such as their agreement with BeiGene. Additionally, they are navigating potential threats from increasing competition and regulatory scrutiny. Overall, Amgen is well-positioned for future growth, but will need to adapt to the rapidly changing healthcare landscape.

Key Financials

Market Cap

$202.60B

Revenue

$36.75B

EBITDA

$17.06B

Gross Margin

70.8%

Profit Margin

21.0%

Revenue Growth

8.6%

Total Cash

$9.13B

Total Debt

$54.60B

Free Cash Flow

$7.60B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

26.41

Forward P/E

16.24

Beta

0.47

52-Week High

$377.88

52-Week Low

$261.43

EPS

$14.23

50-Day Avg

$334.30

200-Day Avg

$302.43

Price/Book

23.40

Technical Analysis

Amgen Inc. (AMGN) has demonstrated a strong uptrend over the past 52 weeks, with a price increase of 34.6%, settling at $375.88. Key support is evident around the $275 level, where the stock found a solid floor several times, while resistance is visible near $384.32, marked by recent price peaks. The chart shows an ascending triangle formation, indicating potential for a breakout if the price pushes above the resistance level. Over the last few weeks, recent momentum has been positive, as the stock price approached the resistance, suggesting bullish sentiment among investors. Currently, the price of $375.88 is positioned near the upper end of the 52-week range, indicating strength and potentially signaling further upward movement, should it successfully break through the resistance level.

Recent News and Developments

Amgen Inc

(AMGN) has experienced a dynamic week with significant analyst activity, positive earnings results, and important regulatory and partnership updates. The company’s stock also saw notable price movements, reaching a new all-time high.

Market Update

Here are 3-5 specific news items from the past week:

### 1

Strong Q4 2025 Earnings and Positive 2026 Guidance
Amgen reported robust fourth-quarter and full-year 2025 financial results on February 3, 2026, surpassing analyst expectations. Total revenues for Q4 increased 9% year-over-year to $9.9 billion, and adjusted earnings per share reached $5.29, significantly higher than the $4.73 forecast by analysts. The company also provided an optimistic outlook for 2026, projecting total revenues between $37.0 billion and $38.4 billion and adjusted EPS between $21.60 and $23.00, anticipating growth to outweigh challenges from increased biosimilar competition.

Market Sentiment and Analyst Recommendations

Bull Case

Amgen just crushed Q4 with 9% revenue growth and beat EPS estimates by 12% ($5.29 vs $4.73 forecast). The 2026 guidance projects $37.0-38.4B in revenue and $21.60-23.00 in adjusted EPS, which implies continued mid-to-high single digit growth despite biosimilar headwinds. Twenty-seven analysts are rated buy, and three just raised price targets post-earnings (Leerink to $355, Cantor to $350, Guggenheim to $347), suggesting conviction in the growth narrative. The stock is up 34.6% over 52 weeks and just hit an all-time high, but trades at only 26.41x forward P/E which is reasonable for a mega-cap pharma with consistent cash generation. The company has $9.13B in cash to fund R&D and M&A, and the ascending triangle formation suggests momentum for a breakout above the $384 resistance level.

Bear Case

The debt load of $54.60B is nearly 6x the cash position, which limits financial flexibility and creates refinancing risk if rates stay elevated. The Tavneos regulatory issue is a red flag – the FDA wants the drug pulled and Amgen is fighting it, meaning potential revenue loss on a rare disease asset if the agency wins. The rocatinlimab termination with Kyowa Kirin signals that even Amgen’s pipeline has disappointments; the drug hit primary endpoints but underperformed versus Dupixent, showing competitive pressure in hot categories. At $375.88, the stock is already near the top of its 52-week range and just 10% below the $425 analyst high target, leaving limited upside if growth disappoints. Biosimilar competition will continue eroding margins on legacy drugs, and the 8.6% revenue growth rate needs to accelerate to justify current valuations as the market matures.

What to Watch

Monitor the Tavneos FDA resolution closely – any forced withdrawal would materially impact rare disease revenue and credibility on pipeline execution. Track 2026 quarterly results against the $9.25-9.60B per-quarter revenue guidance the company implied; misses would trigger a sharp sell-off given how tight analyst estimates are. Watch for the rocatinlimab regulatory path under Kyowa Kirin’s control in H1 2026; if it succeeds independently, Amgen looks foolish for terminating, but failure validates the decision. The stock needs to break above $384.32 resistance to confirm the bullish breakout pattern; a close below $360 would signal momentum loss and potential retest of the $275-300 support zone. Keep tabs on biosimilar launch timelines for key franchises like Enbrel and Neulasta – accelerated generic/biosimilar penetration could force guidance cuts. Finally, watch the debt-to-EBITDA ratio quarterly; if leverage tightens above 2.5x amid slower growth, dividend cuts or M&A slowdown become real possibilities.

Analyst Consensus

BUY

Based on 27 analyst opinions

Low Target

$180.00

Mean Target

$341.93

High Target

$425.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 30, 2026

EPS (Trailing)

$14.23

Dividend Yield

263.0%

Payout Ratio

66.9%

Frequently Asked Questions

Is AMGN a good stock to buy?

Analysts recommend a BUY with a target price of $341.93. Given its current price of $375.88 and a forward P/E of 16.24, it appears overvalued in the short term, but long-term growth potential remains.

What is AMGN’s price target?

The analyst consensus price target for AMGN is $341.93. This suggests a potential downside of about 9% from the current price, indicating cautious sentiment among analysts.

Does AMGN pay a dividend?

Yes, AMGN has a significant dividend yield of 263.0%. This makes it attractive for income-focused investors, although the yield percentage seems unusually high and may warrant further investigation.

What is AMGN’s market capitalization?

Amgen has a market capitalization of $202.60 billion. This positions it as a major player in the healthcare sector, particularly in drug manufacturing.

What is AMGN’s P/E ratio?

AMGN has a P/E ratio of 26.41 and a forward P/E of 16.24. While the current P/E indicates a higher valuation relative to earnings, the forward P/E suggests better earnings growth prospects ahead.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.